NOMASKERS.ORG

Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals


Resources 0 Comments 08/11/2021  
https://clinicaltrials.gov/ct2/show/NCT04368728

Posted By: Fielden Nolan (nolanf)

Brief Summary:

This is a Phase 1/2/3, randomized, placebo-controlled, observer-blind, dose-finding, vaccine candidate-selection, and efficacy study in healthy individuals.

The study consists of 2 parts: Phase 1: to identify preferred vaccine candidate(s) and dose level(s); Phase 2/3: an expanded cohort and efficacy part.

The study will evaluate the safety, tolerability, and immunogenicity of 3 different SARS-CoV-2 RNA vaccine candidates against COVID-19 and the efficacy of 1 candidate:

  • As a 2-dose (separated by 21 days) schedule;
  • At various different dose levels in Phase 1;
  • As a booster;
  • In 3 age groups (Phase 1: 18 to 55 years of age, 65 to 85 years of age; Phase 2/3: ≥12 years of age [stratified as 12-15, 16-55 or >55 years of age]).

The candidate selected for efficacy evaluation in Phase 2/3 is BNT162b2 at a dose of 30 µg.

Participants who originally received placebo will be offered the opportunity to receive BNT162b2 at defined points as part of the study.

In order to describe the boostability of BNT162, and potential heterologous protection against emerging SARS-CoV-2 VOCs, an additional dose of BNT162b2 at 30 µg will be given to Phase 1 participants approximately 6 to 12 months after their second dose of BNT162b1 or BNT162b2. This will provide an early assessment of the safety of a third dose of BNT162, as well as its immunogenicity.

The assessment of boostability will be further expanded in a subset of Phase 3 participants at selected sites in the US who will receive a third dose of BNT162b2 at 30 µg or a third and potentially a fourth dose of prototype BNT162b2VOC at 30 µg (BNT162b2s01, based upon the South African variant and hereafter referred to as BNT162b2SA). A further subset of Phase 3 participants will receive a third, lower, dose of BNT162b2 at 5 or 10 µg.

To further describe potential homologous and heterologous protection against emerging SARS-CoV-2 VOCs, a new cohort of participants will be enrolled who are COVID-19 vaccine-naïve (ie, BNT162b2-naïve) and have not experienced COVID-19. They will receive BNT162b2SA given as a 2-dose series, separated by 21 days.



VIEW News Item

‘Urgent’ British report calls for complete cessation of COVID vaccines in humans

“The MHRA now has more than enough evidence...to declare the COVID-19 vaccines unsafe...”
VIEW News Item

Dr. Mercola: Public Health Officials Are Lying About Lockdowns (video)

CDC Inflated COVID-19 Deaths by 1,670%, Violated Fed Law
VIEW News Item

THE ARREST OF A BROKEN MAN

LOST HIS BUSINESS & THEN ARRESTED FOR PROTESTING
VIEW News Item

Not Just Masks: Biden CDC Surrender Also Includes Changes to Coronavirus Testing for Vaccinated People

“If vaccines work…then why do people who have the vaccine need to now wear masks?”
VIEW News Item

CDC issues new COVID cleaning guidelines

Updated to “reflect the science on transmission.”
VIEW News Item

Legal Help For Religious Exceptions From Vaccinations

Denied? You will first need to file an EEOC Complaint
VIEW News Item

NY: COVID checkpoints are back: Cops will be out 'in force'

Questions Thanksgiving travelers from out of state

VIEW Blog Item

They're Changing the Meaning of Science

Psycho desk jockies and pencil pushers are attempting to redefine science.

We appreciate your donations to NOMASKERS.ORG, because without them this site would not be possible. You do not need a PayPal account in order to donate with your credit card. Just click on the Donate button below. You will be prompted for the amount you wish to contribute.

/* */